Mimedx (MDXG) Gross Margin (2011 - 2026)

Mimedx has disclosed Gross Margin across 16 years of filings, most recently posting 70.56% for Q1 2026.

• Gross Margin for Q1 2026 came in at 70.56%, down 1067.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 81.04% (down 90.0% YoY), and the FY2025 annual result was 82.56%, down 22.0% from the prior year.
• Gross Margin came in at 70.56% for Q1 2026 at Mimedx, down from 83.86% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 84.67% in Q1 2024 to a low of 70.56% in Q1 2026.
• The 5-year median for Gross Margin is 82.32% (2022), against an average of 81.85%.
• Across the five-year window, Gross Margin jumped 338 bps in 2023 and tumbled 1067 bps in 2026, its largest moves.
• Mimedx's Gross Margin stood at 80.68% in 2022, then grew by 4 bps to 84.06% in 2023, then decreased by 3 bps to 81.8% in 2024, then grew by 3 bps to 83.86% in 2025, then dropped by 16 bps to 70.56% in 2026.
• The last three Gross Margin figures came in at 70.56% (Q1 2026), 83.86% (Q4 2025), and 83.54% (Q3 2025), per Business Quant data.